Study of ECC4703 With Sulfasalazine and Pitavastatin

Summary

Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis. The overall prevalence of non-alcoholic fatty liver disease is rapidly rising world-wide. ECC4703 is a potential new treatment for non-alcoholic fatty liver disease. The purpose of this research is to investigate the safety, tolerability and pharmacokinetics of sulfasalazine and pitavastatin when combined with ECC4703.

Eligibility

Inclusion Criteria:

* Male or female between the ages of 18 and 65 years, inclusive, at the time of Screening.
* Are healthy and in the opinion of the Investigator have an acceptable medical history (free from significant cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, neurological, infective, or psychiatric diseases as determined by medical history over the past 5 years, physical examination, vital signs, 12-lead ECG, and clinical laboratory tests).
* Has not consumed and agrees to abstain from taking any prescription drugs or non-prescription drugs for 7 days or 5 half-lives (whichever is longer) prior to first dose of trial treatment and continuing through end of the Treatment Period.

Exclusion Criteria:

* Has a history of significant renal, hepatic, cardiovascular, psychiatric, neoplastic, thyroid disease/abnormality or other disease which, in the opinion of the Investigator, represents a safety risk for taking part in the trial.
* Has a history of sensitivity to any of the trial treatments (and/or their excipients), or severe drug or other allergy
* Has a history of drug abuse within the previous 2 years, or a positive drug screen at Screening and/or Day -1.
* Regular consumption of more than 10 standard alcoholic drinks/week and/or more than 4 standard alcoholic drinks on any one day
* Has a history or current diagnosis of a significant psychiatric disorder that would, in the opinion of the Investigator, affect the participant's ability to comply with the trial requirements.
* Has a personal or family history of hereditary muscular disorders, previous statin-induced myopathy/rhabdomyolysis, or unexplained repeated or severe muscle pain.
* Has a history of any unexplained chronic skin rash or autoimmune skin diseases.
* Has a personal or family history of Stevens-Johnson syndrome (SJS), or other severe drug-induced skin reactions.
* History of surgery or hospitalisation within 3 months prior to screening, or surgery planned during the study.

Conditions3

Interventions3

Related trials

• A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) — Eccogene
• PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC) — University of California, Irvine
• Glutamate Inhibitors in Glioblastoma — University of Zurich
• Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment — Assistance Publique - Hôpitaux de Paris
• Sulfasalazine in Patients With Metastatic Colorectal Cancer — Tanta University
• Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response — University of Nebraska
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty — NYU Langone Health

Browse More Trials